Author

V. Abbiento

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

C. Sala· 5 shared E. Andreano· 5 shared R. Rappuoli· 5 shared I. Paciello· 4 shared C. De Santi· 3 shared E. Montomoli· 3 shared E. Pantano· 3 shared G. Antonelli· 3 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. Sala

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens

M. Troisi, M. Fabbrini, S. Stazzoni, V. Viviani, F. Carboni, V. Abbiento, L. E. Fontana, S. Tomei, M. Audagnotto, L. Santini, A. Spagnuolo, G. Antonelli, I. Paciello, F. Vacca, D. Cardamone, , An

The paper identifies human monoclonal antibodies that recognize key antigens, PorB and LOS, providing cross-protection against gonococcal and meningococcal infections.

bioRxiv · Dec 7, 2023 · PreprintImmunology

High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae

S. Stazzoni, M. Troisi, V. Abbiento, C. Sala, E. Andreano, R. Rappuoli

This study develops high-throughput bactericidal assays to screen monoclonal antibodies against antimicrobial-resistant Neisseria gonorrhoeae, identifying potent antibodies validated by conventional methods.

bioRxiv · May 10, 2023 · PreprintMicrobiology

mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5

E. Andreano, I. Paciello, G. Pierleoni, G. Maccari, G. Antonelli, V. Abbiento, P. Pileri, L. Benincasa, G. Giglioli, G. Piccini, C. De Santi, C. Sala, D. Medini, E. Montomoli, P. Maes, R. Rappuoli

The paper compares neutralizing antibodies against Omicron BA.4 and BA.5 from mRNA-vaccinated individuals and those with hybrid immunity, finding differences in epitope targeting and B cell germlines used.

bioRxiv · Aug 4, 2022 · PreprintImmunology

SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly

A. Onnis, E. Andreano, C. Cassioli, E. Pantano, V. Abbiento, G. Marotta, R. Rappuoli, C. T. Baldari

This study shows SARS-CoV-2 Spike protein inhibits CTL immune synapse formation by binding ACE2, reducing target cell killing.

bioRxiv · May 20, 2022Immunology

COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response

E. Andreano, I. Paciello, G. Pierleoni, G. Piccini, V. Abbiento, G. Antonelli, P. Pileri, N. Manganaro, E. Pantano, G. Maccari, S. Marchese, L. Donnici, L. Benincasa, G. Giglioli, M. Leonardi, , R. Rappuoli

This study examines how a third mRNA vaccine dose enhances neutralizing antibody responses against SARS-CoV-2 variants by expanding specific B cell germlines and altering the antibody repertoire.

bioRxiv · May 9, 2022 · PreprintImmunology

Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern

E. Andreano, I. Paciello, G. Piccini, N. Manganaro, P. Pileri, I. Hyseni, M. Leonardi, E. Pantano, V. Abbiento, L. Benincasa, G. Giglioli, C. De Santi, M. Fabbiani, I. Rancan, M. Tumbarello, , R. Rappuoli

This study compares B cell responses in naive and convalescent individuals after SARS-CoV-2 vaccination, showing convalescents have higher frequency and broader neutralizing antibody responses against variants.

bioRxiv · Aug 12, 2021 · PreprintImmunology